To see all protocols that comply with the WHO Essential Medicine List 

Welcome to eviQ

A free resource of evidence-based, consensus driven cancer treatment protocols and information for use at the point of care. eviQ is developed for the Australian context and supports health professionals in the delivery of cancer treatments.

Find out more

 

Latest news

View all news

Module 2: Haematological diseases and disorders is available now, developed in collaboration with the Agency for Clinical Innovation NSW.

BOPA have produced a guideline on the use of H2 antagonists for hypersensitivity; accessed via link below. BOPA members are encouraged to participate in a national service evaluation of paclitaxel pre-medication regimes, please contact BOPA for more information.

We have created a specific page to link relevant COVID-19 resources for cancer health professionals and people with cancer and their carers.

**Reference Committee Update** The production of L-asparaginase (also known as colaspase or brand name Leunase) has been discontinued by the manufacturer. This will impact a number of eviQ protocols.